Rigel Pharmaceuticals | RIGL - Cost Of Sales


Rigel Pharmaceuticals reported $8.03M in Cost of Sales for its fiscal quarter ending in September of 2024.





Cost Of Sales Change Date
Agenus USD 137K 19K Mar/2025
Amgen USD 1.79B 128M Dec/2025
Anika Therapeutics USD 11.49M 35.48M Mar/2025
AstraZeneca USD 3.27B 471M Dec/2025
BioMarin Pharmaceutical USD 144.93M 10M Sep/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Celldex Therapeutics USD 54.2M 8.94M Jun/2025
Daiichi Sankyo JPY 118.28B 37.7B Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Halozyme Therapeutics USD 73M 8.88M Sep/2025
Heron Therapeutics USD 9.46M 1.61M Sep/2024
Intrexon USD 1.01M 344K Jun/2024
Ionis Pharmaceuticals USD 2.34M 1.81M Sep/2025
Karyopharm Therapeutics USD 37.43M 2.41M Sep/2024
Ligand Pharmaceuticals USD 11.9M 733K Sep/2025
MacroGenics USD 44.3M 5.4M Sep/2025
Neurocrine Biosciences USD 264M 252.7M Sep/2025
Pfizer USD 6.29B 2.12B Dec/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Rigel Pharmaceuticals USD 8.03M 5.22M Sep/2024
Sangamo BioSciences 2.42M 1.11M Jun/2024
Ultragenyx Pharmaceutical USD 27.99M 4.99M Sep/2025
Veracyte USD 41.21M 196K Sep/2025